Core Insights - Company has entered into a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, marking the seventh partnership between the two entities [1] - The collaboration aims to leverage complementary strengths to accelerate the global development of innovative drugs, with the company leading projects from drug discovery to clinical concept validation in China [1] - Eli Lilly will obtain exclusive global development and commercialization rights outside Greater China, while the company retains all rights within Greater China [1] Financial Terms - The agreement includes an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion based on specific future milestones [2] - The company is entitled to a tiered sales share from net sales of each product outside Greater China [2] Collaboration Model - This partnership breaks traditional licensing models, creating a seamless end-to-end innovation ecosystem that integrates the company's flexible drug discovery and early development capabilities with Eli Lilly's extensive global presence [2] - The collaboration underscores the company's core R&D capabilities and aims to expedite the translation of scientific discoveries into globally impactful medical solutions [2]
信达生物与礼来制药达成全球战略合作推进肿瘤及免疫领域的新药开发